Vaccine Breaking News

Vaccine breaking news brought to you by Precision Vaccinations.

Aug 12, 2022 • 2:44 pm CDT
by T. Garcia

The New York State Department of Health (NYSDOH) and the New York City Department of Health and Mental Hygiene (NYCDOHMH) updated New Yorkers today on the detection of poliovirus in sewage.

This finding suggests likely local circulation of the virus in NYC that can lead to permanent paralysis of the arms and legs and even death in some cases.

These findings follow the identification of a case of paralytic polio among a Rockland County resident on July 21, 2022, and the detection of poliovirus in wastewater samples collected in May, June, and July from Rockland and Orange Counties in lower New York.

As of August 1, 2022, Rockland County had a polio vaccination rate of about 60%, and Orange County at 58%.

"The risk to New Yorkers is real, but the defense is so simple – get vaccinated against polio," said Health Commissioner Dr. Ashwin Vasan in a press release on August 12, 2022. 

"With polio circulating in our communities, there is simply nothing more essential than vaccinating our children to protect them from this virus."

"And if you're an unvaccinated or incompletely vaccinated adult, please choose now to get the vaccine."

"Polio is entirely preventable, and its reappearance (in NYC) should be a call to action for all of us."

In NYC, children four years and older can get low- or no-cost vaccines at the NYC Health Department's Fort Greene Health Center at 295 Flatbush Ave. Ext., Fifth Floor, Brooklyn, NY, from Monday to Friday, 8:30 a.m. to 2:30 p.m. To make an appointment, visit and search for an immunization clinic.

"For every one case of paralytic polio identified, hundreds more may be undetected," State Health Commissioner Dr. Mary T. Bassett added

"The detection of poliovirus in wastewater samples in NYC is alarming, but not surprising."

The percentage of children who received three doses of polio vaccine in NYC as of June 30, 2022, was about 86%, with some sections reporting a below 60% vaccination rate.

In the USA, combination and single polio vaccines are available in pediatrician practices and local pharmacies.

Additional polio outbreak news is posted at

Aug 12, 2022 • 11:01 am CDT
by mohamed Hassan

In the last decade, the Respiratory syncytial virus (RSV) vaccine landscape has significantly transitioned from empirical to rational vaccine design. 

To offer keen insights, The Lancet published a Review on August 8, 2022, that characterized the dynamics of the RSV vaccine and treatment landscape, which included multiple late-phase failures and new, innovative vaccine candidates.

The number of RSV candidates in late-phase development is expanding.

A better understanding of RSV neutralizing epitopes has rapidly expanded to the nine vaccine candidates currently conducting late-stage phase 3 trials.

Although the approval of multiple RSV vaccines is within reach, several obstacles to worldwide access remain.

Globally representative clinical studies are needed in countries with the highest disease burden as efficacy can differ based on local populations.

Overall, 'we are at an exciting phase of vaccine and mAb development in which RSV prevention is within reach, wrote these researchers.

'It is likely that multiple immunization strategies with complementary value, unique advantages, and use-case scenarios will shape the RSV prevention landscape.'

'To guarantee worldwide access, urgent steps are required to surmount challenges of measuring protection, monitoring viral resistance, and prioritizing access and affordability.'

To read the entire RSV review, please visit The Lancet.

The U.S. NIH stated in June 2022 that RSV is one of the most common viruses to infect children worldwide and is increasingly recognized as an important pathogen in adults, especially the elderly.

RSV is a widespread pathogen due in part to the lack of long-term immunity after infection, making reinfection frequent.

It infects 90% of children within the first years of life and frequently reinfects older children and adults. 

The most common clinical scenario encountered in RSV infection is an upper respiratory infection.

But RSV commonly presents in young children as bronchiolitis, a lower respiratory tract illness with small airway obstruction, and can rarely progress to pneumonia, respiratory failure, apnea, and death.

Additional RSV vaccine and mAbs news are posted at

Aug 12, 2022 • 10:07 am CDT
from Pixabay

South San Francisco-based Genentech recently announced that the U.S. FDA had approved a supplemental New Drug Application (sNDA) for Xofluza® (baloxavir marboxil) for the treatment of uncomplicated acute influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more than 48 hours. 

This approval marks the first single-dose oral influenza medicine approved for children in this age group.

Additionally, the FDA approved Xofluza for the prevention (post-exposure prophylaxis) of influenza in children aged five to less than 12 years following contact with someone with flu.

Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development, stated in a press release issued on August 11, 2022, "Xofluza has proven to be an important tool in fighting and preventing influenza in adults as well as adolescents."

"And we are pleased to offer our single-dose oral treatment to households and younger children."

Xofluza is already FDA-approved for use in older children and adolescents.

It is a first-in-class, single-dose oral medicine with an innovative proposed mechanism of action that has demonstrated efficacy in a wide range of influenza viruses, including in vitro activity against oseltamivir-resistant strains and avian strains (H7N9, H5N1) in non-clinical studies.

And is the first in a class of antivirals designed to inhibit the cap-dependent endonuclease protein, which is essential for viral replication.

This announcement is essential for the pediatric population since influenza continues to impact children negatively.

 As of August 5, 2022, the U.S. CDC reported (33) pediatric influenza-related deaths were confirmed during the 2021-2022 flu season. 

Last flu season, only (1) flu-related pediatric fatality was confirmed.

Additional flu vaccine and medication news are posted at

Note: This Genentech announcement was manually curated for mobile readers.

Aug 12, 2022 • 9:15 am CDT
by Messan Edoh

New York-based Pfizer Inc. today announced positive top-line results from its pivotal U.S. Phase 3 clinical study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae serotypes contained in the vaccine.

The study had two co-primary objectives, associated with immunogenicity responses one month after the third and fourth doses of the four-dose vaccination series, respectively:

  • Non-inferiority (NI) of the percentage of participants with predefined serotype-specific immunoglobin G (IgG) concentrations after Dose 3 and NI of IgG geometric mean concentrations (GMCs) after Dose 4.
  • All 20 serotypes met the co-primary objective of NI of IgG GMCs after Dose 4.
  • Fourteen of the 20 serotypes met the co-primary objective of NI of the percentage of participants with predefined IgG levels after Dose 3 (two serotypes missed by a wider margin while four narrowly missed).
  • And all serotypes met non-inferiority for the key secondary objective of IgG GMCs after Dose 3.
  • All 20 serotypes elicited robust functional responses (OPA) and increases in antibody responses after Dose 4, with the totality of data supporting the potential benefit of all serotypes in this 20-valent vaccine candidate.

“We are encouraged by today’s data which show that if approved for a pediatric indication, 20vPnC would have the potential to cover more of the clinically significant remaining burden of infant pneumococcal disease than any other available pneumococcal conjugate vaccine,” said Annaliesa Anderson, Ph.D., SVP and Chief Scientific Officer, Vaccine Research and Development, Pfizer, in a press release issued on August 12, 2022.

Overall, the safety profile of the 20vPnC candidate was consistent with Prevnar 13 given in the same schedule.

This study also met non-inferiority objectives for responses to co-administered routinely used pediatric vaccines.

Based on the totality of favorable safety and immunogenicity data, Pfizer stated it plans to submit a supplemental Biologics License Application (sBLA) by the end of 2022, subject to discussions with the U.S. FDA.

Additional top-line results from other pediatric 20vPnC clinical trials are expected to read out in the second half of 2022, with discussions with other regulatory bodies planned once those pivotal data become available, stated the company.

Other pneumococcal vaccine news is posted at

Note: This press release was manually curated for mobile readers.

Aug 12, 2022 • 2:39 am CDT
Bavarian Nordic

Denmark-based Bavarian Nordic CEO Paul Chaplin sent a letter to U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra and FDA Commissioner Robert Califf expressing safety concerns on August 9, 2022, about the alternative monkeypox vaccine dosage strategy the USA has launched.

Bavarian Nordic is the manufacturer of the Jynneos monkeypox vaccine currently approved by the U.S. FDA and offered to people throughout the USA.

In the letter obtained by Dan Diamond with the Washington Post, Chaplin stated, "Bavarian Nordic is dedicated to assisting Governments around the globe to control the current monkeypox outbreak and is fully supportive of dose-sparing approaches, such as delaying the second vaccination."

"However, we do have some reservations on the ID [intradermal] approach due to the very limited safety data available (<200 people)."

"We have been made aware of some additional analysis of the ID study data."

"But essentially, this does not change the overall picture that the ID administration results in increased reactogenicity compared to subcutaneous, and this may have a negative impact on vaccine uptake and coverage."

"Since last Thursday, we have been inundated with calls from U.S. government officials with questions and concerns regarding the ID administration."

"For these reasons, we believed it would have been prudent that the rollout of the FDA's EUA be supported by an implementation protocol."

"And the fact that there was a relatively high percentage of subjects (20%) that failed to receive the second vaccination during a controlled clinical study."

"We will, of course, align our responses with our colleagues at the U.S. CDC, but we believe this alignment would have been better served before any announcement to ensure the best rollout of the EUA."

To clarify the clinical aspects of these changes, the CDC published updated 'interim guidance' on August 10, 2022.

Additionally, Chaplin indicated in his letter the company might have access to more Jynneos vaccines than initially calculated.

As of August 8, 2022, the U.S. HHS Office of the Assistant Secretary for Preparedness and Response had delivered about 617,693 Jynneos vaccine doses from the Strategic National Stockpile to U.S. jurisdictions. 

And on July 21, 2022, HHS confirmed the federal government would have access to more than 6.9 million Jynneos doses by mid-2023. 

Other monkeypox vaccine news, including the ACAM2000 vaccine and TPOXX treatment, are posted at

Note: This letter was manually translated and curated for mobile readership.

Aug 11, 2022 • 6:18 pm CDT
by 冠霖 黃 from Pixabay

Nearly 100 years old, the bacille Calmette-Guérin (BCG) vaccine continues offering disease protection. According to a recent study funded by the U.S. NIH, 'BCG vaccination at birth is effective at preventing tuberculosis (TB) in young children.

But BCG vaccination is ineffective when administered in adolescents and adults.

Therefore, TB immunoprotection needs to be boosted in older populations.

Published in The Lancet Global Health as an early release for September 2022 and led by BU School of Public Health researchers, this study offers new insight and clarity on the BCG vaccine's continued value. 

"Unlike many of the mRNA COVID-19 vaccines, which we know are highly effective, there is widespread debate on the BCG vaccine's effectiveness and duration of protection, as well as whether the vaccine only works in selective settings," says study lead author Leonardo Martinez, assistant professor of epidemiology, in a press release on August 9, 2022.

"Our findings indicate that BCG vaccination is effective at preventing tuberculosis in young children. However, since tuberculosis in children is a highly debilitating and severe disease, BCG vaccination should continue to be used."

Martinez added, "Novel vaccines are urgently needed to supplement BCG vaccination in high-burden settings."

These findings provide up-to-date assessments of BCG vaccine effectiveness against TB.

This new analysis presents data over the past ten years from high-burden settings in 17 countries, including South Africa, China, Vietnam, Indonesia, Uganda, The Gambia, and Brazil.

The BCG vaccine is seldom offered in the USA since TB was eradicated years ago.

In addition to TB, the BCG vaccine has been found effective against various diseases, such as meningitis and bladder cancer.


Aug 11, 2022 • 5:00 pm CDT

Since mid-May 2022, the U.S. government has combated the escalating monkeypox outbreak by establishing a new leadership team, committing substantial economic resources, and recently announcing innovative vaccination schedules. 

However, the number of people directly impacted has exceeded 10,000, with an unknown amount of close contacts undiagnosed.

"In recent weeks, the monkeypox virus has continued to spread at a rate that has made it clear our current vaccine supply will not meet the current demand," said FDA Commissioner Robert M. Califf, M.D., in a press release on August 9, 2022.

"The FDA quickly explored other scientifically appropriate options to facilitate access to the vaccine for all impacted individuals."

"By increasing the number of available doses, more individuals who want to be vaccinated against monkeypox will now have the opportunity to do so."

Jynneos, the Modified Vaccinia Ankara vaccine, was approved in 2019 to prevent smallpox and monkeypox disease in adults determined to be at high risk for smallpox or monkeypox infection.

It is usually administered beneath the skin (subcutaneously) in two doses, four weeks apart.

For individuals 18 years of age and older determined to be at high risk of monkeypox infection, the U.S. FDA EUA now allows for a fraction of the dose to be administered between the layers of the skin (intradermally).

No data is currently available to indicate that one dose of Jynneos will provide long-lasting protection.

This disclosure indicates two full doses of Jynneos are still needed to produce maximum immunity to the monkeypox virus.

And to clarify vaccination questions, the U.S. CDC updated interim guidance on August 10, 2022.

Other monkeypox vaccination information is posted at

Aug 10, 2022 • 3:23 pm CDT
The Lancet

With the subsiding COVID-19 pandemic control measures, new data from the Southern Hemisphere indicates the return of influenza may significantly impact public health in the USA.

According to a Correspondence published by The Lancet on August 3, 2022, there has been a rapid rise in influenza A notifications in Australia during the winter season.

Most years, data from Australia helps predict what is coming to the Northern Hemisphere in the fall.

As of June 19, 2022, about 85% of influenza cases in Australia were due to influenza A (H3N2), which is known to cause more severe epidemics.

These researchers stated 'children are responsible for most influenza transmission in Australia, where 10–14-year-olds currently have one of the highest infection rates.'

Therefore, 'vaccinating children is particularly important,' wrote these researchers. 

However, to be effective, influenza vaccination campaigns should start early in the flu season.

In the USA, the flu season generally starts after the Labor Day holiday and lasts well into spring.

The U.S. CDC suggests most people over the age of six months get a flu shot as soon as they become available.

This recommendation is essential since (33) pediatric influenza-related deaths have been confirmed during the 2021-2022 flu season.

And for certain at-risk people, a flu shot booster is also encouraged later in the season.

According to media reports, over 100 million influenza vaccines will soon arrive in clinics and local pharmacies.

Last flu season, about 175 million flu shots were administered.

Furthermore, the U.S. FDA's Vaccines and Related Biological Products Advisory Committee recently endorsed influenza and COVID-19 vaccine co-administration.

And for the first time, the CDC is endorsing certain high-power flu shots for older adults.

Additional flu shot news is posted at

Aug 10, 2022 • 10:36 am CDT
by Dean Moriarty

The U.S. CDC published 'Interim Clinical Considerations for the use of monkeypox vaccines during the 2022 outbreak, which started in the USA on May 17, 2022. Since then, over 9,493 people have been impacted.

As of August 9, 2022, this CDC document provides new guidance for healthcare professionals and public health officials regarding using JYNNEOS and ACAM2000 vaccines.

This interim guidance is in addition to existing standard guidance and recommendations for using these vaccines from the CDC's Advisory Committee on Immunization Practices.

The term interim implies that CDC developed these guidelines using either expert opinion, indirect evidence, or emerging evidence, and these recommendations might change when additional evidence becomes available.

This document is informed by data and considerations from U.S. federal agencies, including the Assistant Secretary for Preparedness and Response (ASPR), FDA, NIH, and CDC, general best practice guidelines for immunization, other data sources, and expert opinion.

These CDC considerations apply only to monkeypox (MPX) vaccines in the USA.

As of August 8, 2022, ASPR, in partnership with the CDC, had delivered 617,693 Jynneos vaccines in the USA.

Globally, over eighty countries have reported about 34,000 MPX cases.

Additional monkeypox outbreak news is posted at Vax-Before-Travel.

Note: This CDC information was manually curated.

Aug 10, 2022 • 8:29 am CDT
by Adrian from Pixabay

Massachusetts-based Moderna, Inc. announced yesterday an amendment to its agreement with the European Commission (EC) to convert contractually agreed doses of Moderna's COVID-19 vaccine (Spikevax, mRNA-1273) to the Company's Omicron-containing bivalent vaccines for supply in 2022, pending regulatory approval by the European Medicines Agency (EMA).

Under the amendment, contractually scheduled doses in July and August of Moderna's COVID-19 vaccine will be deferred to later in 2022, with all remaining contractually agreed doses of mRNA-1273 converted to Omicron-containing bivalent vaccines, pending EMA approval.

In addition, the EC has agreed to purchase an additional 15 million doses of Omicron-containing vaccine booster candidates from Moderna.

Moderna is advancing two bivalent candidates for utilization in global vaccination efforts.

The mRNA-1273.214 bivalent booster candidate is based on the Omicron subvariant BA.1 and has demonstrated favorable clinical data against variants of concern, including Omicron.

The second bivalent booster candidate, mRNA 1273.222, is based on the BA.4/5 strain.

Both bivalent candidates contain 25 µg of the currently authorized booster (mRNA-1273) and 25 µg of an Omicron-specific subvariant.

"The European Commission and Moderna have been steadfast partners in the fight against the COVID-19 pandemic. This agreement highlights the EC's trust in our mRNA platform and next-generation bivalent COVID-19 vaccines," said Stéphane Bancel, Moderna's CEO, in a press release issued on August 9, 2022.

"Participating member states will now have access to Omicron-containing vaccine booster candidates and protection against COVID-19, heading into the winter season."

The U.S. NIH Opendata portal displays interim variant activity data as of August 4, 2022.

On August 3, 2022, Moderna announced $10.8 billion in revenue for the first half of 2022.

"We continue to have advance purchase agreements for expected delivery in 2022 of around $21 billion of sales," added Bancel.

Note: This information was manually curated for mobile readership.

Aug 10, 2022 • 5:17 am CDT
Novavax Inc.

Gaithersburg, MD-based Novavax Inc. recently announced adjusted financial guidance for 2022 to account for several evolving market dynamics. For the second quarter of 2022, total company revenue of $186 million included $78 million of product sales/royalties from the protein-based COVID-19 vaccine (NVX-CoV2373).

And the company revised the full year 2022 total revenue guidance to $2 to $2.3 billion.

'We remain confident in our (COVID-19) vaccine as a strong additional choice,' stated Novavax on August 8, 2022.

'We have built a global presence with authorizations (Nuvaxovid or Covovax) in 43 countries and Emergency Use Listing with the WHO.

In the U.S., 'we have successfully brought our vaccine to market under U.S. FDA Emergency Use Authorization, and vaccinations are now underway in 47 states.'

'Its competitive product profile includes our vaccine's efficacy, well-tolerated safety profile, the durability of protection, and ability to address both current and future variant strains,' stated the company on August 8, 2022.

'In Q32022, we are already making tremendous progress. We have shipped over 23 million COVID-19 vaccine doses since the beginning of July 2022.'

'Overall, we remain committed to developing new first-in-class vaccine candidates with the potential to address today's most urgent global health needs, including both our COVID-19-Influenza combination and a stand-alone influenza vaccine expected to be in Phase 3 next year (2023),' concluded the company's statement.

Note: Novavax's statements were manually curated for mobile readers.

Aug 9, 2022 • 7:50 am CDT
by Pete Linforth

New York City-based SIGA Technologies, Inc. today announced the exercise of procurement options under its contract with the U.S. Department of Health and Human Services (HHS) for the delivery of intravenous (IV) formulation of TPOXX® treatment courses valued at approximately $26 million.

TPOXX, also known as tecovirimat and ST-246®, is a U.S. FDA-approved antiviral drug for treating human diseases caused by the variola virus, such as smallpox and monkeypox.

Product deliveries of IV TPOXX in connection with these contract options are targeted for 2023.

IV TPOXX is an essential option for people with Dysphagia, who cannot swallow, which impacts millions of children and adults.

These contract option exercises represent the first procurement option exercises for IV TPOXX under the 75A50118C00019 (19C) contract.

“These option exercises for the procurement of IV formulation of TPOXX as well as the funding of a post-marketing field study for IV TPOXX highlight the growing importance of a broad-based response to the substantial risks posed by the orthopox family of viruses, including smallpox and monkeypox,” said Phil Gomez, CEO of SIGA, in a press statement issued on August 9, 2022.

The procurement options, which were exercised by the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Administration for Strategic Preparedness and Response at the U.S. HHS, include the manufacture of bulk drug substance and the use of such substance to manufacture and deliver final drug product of IV TPOXX. 

As of August 1, 2022, the U.S. CDC posted information updating the TPOXX ordering process.

The CDC and FDA have made it easier for healthcare providers to provide TPOXX to patients infected with monkeypox under the expanded access investigational new drug process.

However, the FDA confirmed on July 29, 2022, that there is currently no human data demonstrating the efficacy of TPOXX for the treatment of monkeypox or the safety and pharmacokinetic profile.

Additional monkeypox treatment options are reviewed on

Note: This SIGA press release was manually curated for mobile readers.

Aug 8, 2022 • 4:08 pm CDT
by Gerd Altmann

France-based Valneva SE and Pfizer Inc. today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR), to investigate the efficacy, safety, and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15.

As of August 8, 2022, VLA15 is the only Lyme disease vaccine candidate currently in clinical development.

The VALOR study plans to enroll approximately 6,000 participants 5 years of age and older.

It is being conducted at up to 50 sites in areas where Lyme disease is highly endemic, including Finland, Germany, the Netherlands, Poland, Sweden, and the USA.

The study participants will receive four doses; three doses of VLA15 180 µg or saline placebo as a primary vaccination series, followed by one booster dose of VLA15 or saline placebo (1:1 ratio).

Pending successful completion of the Phase 3 study, Pfizer could potentially submit a Biologics License Application to the U.S. FDA and Marketing Authorisation Application to the European Medicines Agency in 2025.

"With increasing global rates of Lyme disease, providing a new option for people to help protect themselves from the disease is more important than ever," said Annaliesa Anderson, Ph.D., SVP and Head of Vaccine Research & Development at Pfizer, in a related press release.

Lyme disease is a systemic infection caused by Borrelia burgdorferi bacteria transmitted to humans by infected Ixodes ticks. It is considered the most common vector-borne illness in the Northern Hemisphere.

While the true incidence of Lyme disease is unknown, it is estimated to affect approximately 476,000 people annually in the USA and 130,000 people in Europe.

"We hope that the data generated from the Phase 3 study will further support the positive evidence for VLA15 to date, and we are looking forward to collaborating with the research sites across the U.S. and Europe on this important trial," added Dr. Anderson.

This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease.

OspA is a surface protein expressed by the bacteria when present in a tick.

Blocking OspA inhibits the bacterium's ability to leave the tick and infect humans.

The VLA15 vaccine covers the six most common OspA serotypes expressed by the Borrelia burgdorferi sensu lato species prevalent in North America and Europe.

Data from the Phase 2 studies continue to demonstrate strong immunogenicity in adults and children, with acceptable safety and tolerability profiles in both study populations.

Note: This press release was manually curated for mobile readers.

Aug 8, 2022 • 3:35 pm CDT
by Alexa P

A recent non-peer-reviewed study conducted in Paris, France, describes the outcomes of high-risk contacts receiving the third-generation IMVANEX® (Jynneos) vaccine as an early postexposure ring vaccination (EPRV) and potential monkeypox virus (MPXV) breakthrough infections after the first dose.

In this cohort of 276 individuals vaccinated with IMVANEX at the Bichat Claude Bernard University Hospital between May 27 and July 13, 2022, 4% (12) of the participants had MPXV breakthrough infections.

Ten of these 12 patients developed an MPXV infection in the five days following the first vaccination, and two others had a breakthrough infection at 22 and 25 days.

Ten other patients declared skin lesions compatible with an MPXV infection on the study questionnaire.

However, six had a negative PCR, and four declined to return to the center for PCR testing.

Since the incubation of the MPXV has been described to range from 5 to 21 days, delaying the second vaccination may be too late to prevent the disease in some patients, stated these researchers on August 4, 2022.

'A previous phase 1 study found that with a single dose of the IMVANEX (MVA) smallpox vaccine in humans, the peak of antibody titer was reached at day 14 with a decrease of antibodies until the second dose of vaccine.'

Therefore, the fact that 10 out of 12 cases occurred five days after vaccination is not surprising.

We were more surprised by the two cases in which the infection occurred after 20 days.

Whether the decrease of antibodies from day 14 may explain the late breakthrough infections, especially if the patient had a new exposure to the Monkeypox virus, cannot be confirmed based on our data but could be a hypothesis.

We did not find any new exposure for these two patients, but they were the only patients out of the 12 who possessed a pet animal.

The pet could theoretically be a reason for persistent exposure in these patients as domestic animals such as cats and dogs can be infected with Monkeypox virus.'

Bavarian Nordic Jynneos smallpox (Monkeypox) vaccine is authorized by the U.S. FDA, the EMA, and the U.K.

Additional monkeypox research is posted on this webpage.

Note: This study was translated and curated for mobile readership. And these researchers did not disclose any industry conflicts of interest.

Aug 6, 2022 • 4:11 am CDT
by Yair Ventura Filho

The West Virginia Department of Health and Human Resources confirmed reports people had developed influenza-like illness after working closely with swine (pigs) at the Jackson County Fair.

In addition, laboratory Services returned presumptive positive influenza A(H3N2) variant (A(H3N2)v) virus on at least one child specimen, reported to the U.S. CDC on August 5, 2022.

This is the first influenza A(H3N2)v virus identified in the USA in 2022.

The patient is a child < 18 years, was not hospitalized, and is recovering from their illness.

No person-to-person spread of this virus has been identified in this case.

“If experiencing symptoms such as fever, runny nose, sore throat, cough or congestion, it is extremely important to let your healthcare provider know if you or your loved one has visited a recent outdoor event with swine and to be appropriately evaluated,” said Dr. Ayne Amjad, in a media statement on August 3, 2022. 

“These symptoms usually show up 1-3 days after exposure.”

When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a Zoonontic “variant influenza virus.”

These infections are relatively rare but happen sporadically.

Additional information on influenza in swine, variant influenza virus infection in humans, and guidance to interact safely with swine can be found at

Furthermore, U.S. FDA-approved flu shots are not protective against swine influenza A(H3N2).

And information regarding Zoonotic influenza and the ongoing avian influenza (HAPI) outbreak in the USA are updated regularly.

Note: this news was manually curated for mobile readers.